alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 520.2605 Trimeprazine and prednisolone capsules. ( a ) *Specifications.* Each capsule contains: ( 1 ) 3.75 milligrams (mg) trimeprazine in sustained released form (as trimeprazine tartrate) and 1 mg prednisolone (Capsule No. 1); or
( 2 ) 7.5 mg trimeprazine in sustained release form (as trimeprazine tartrate) and 2 mg prednisolone (Capsule No. 2).
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer orally once daily an initial dosage: ( i ) For dogs weighing up to 10 pounds: one Capsule No. 1;
( ii ) For dogs weighing 11 to 20 pounds, one Capsule No. 2 or two Capsule No. 1;
( iii ) For dogs weighing 21 to 40 pounds, two Capsule No. 2 or four Capsule No. 1; and
( iv ) For dogs weighing over 40 pounds, three Capsule No. 2 or six Capsule No. 1. After 4 days, the dosage is reduced to approximately 1 ⁄ 2 the initial dosage or to an amount just sufficient to maintain remission of symptoms.
( 2 ) *Indications for use.* For the relief of itching regardless of cause; and for reduction of inflammation commonly associated with most skin disorders of dogs such as eczema, caused by internal disorders, otitis, and dermatitis, allergic, parasitic, pustular and nonspecific. As adjunctive therapy in various cough conditions including treatment of “kennel cough” or tracheobronchitis, bronchitis including allergic bronchitis, in tonsillitis, acute upper respiratory infections and coughs of nonspecific origin.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28833, May 20, 2014]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               DEC-27-1998
<CASH>                                          29,082
<SECURITIES>                                         0
<RECEIVABLES>                                  556,229
<ALLOWANCES>                                    57,618
<INVENTORY>                                    581,922
<CURRENT-ASSETS>                             1,151,939
<PP&E>                                         945,207
<DEPRECIATION>                                 375,521
<TOTAL-ASSETS>                               2,485,198
<CURRENT-LIABILITIES>                          609,176
<BONDS>                                      1,269,913
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           213
<OTHER-SE>                                     278,320
<TOTAL-LIABILITY-AND-EQUITY>                 2,485,198
<SALES>                                      1,824,198
<TOTAL-REVENUES>                             1,824,198
<CGS>                                        1,359,060
<TOTAL-COSTS>                                1,359,060
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                18,122
<INTEREST-EXPENSE>                              83,202
<INCOME-PRETAX>                               (26,354)
<INCOME-TAX>                                    23,644
<INCOME-CONTINUING>                           (49,689)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                    301
<CHANGES>                                            0
<NET-INCOME>                                  (49,990)
<EPS-PRIMARY>                                   (2.35)
<EPS-DILUTED>                                   (2.35)
        

</TABLE>
COURT OF APPEALS

SEVENTH DISTRICT OF TEXAS

AMARILLO

MANDATE

THE STATE OF TEXAS

To the 364th District Court of Lubbock County, Greeting:

BEFORE our Court of Appeals for the Seventh District of Texas, on October 21,

2014, the cause upon appeal to revise or reverse your judgment between

Andre Norris v. The State of Texas

Case Number: 07-13-00116-CR Trial Court Number: 2013-437,508

was determined and therein our said Court made its order in these words:

Pursuant to the opinion of the Court dated October 21, 2014, it is ordered,

adjudged and decreed that the judgment of the trial court be affirmed.

Inasmuch as this is an appeal in forma pauperis, no costs beyond those that

have been paid are adjudged.

It is further ordered that this decision be certified below for observance.

o O o

WHEREFORE, WE COMMAND YOU to observe the order of said Court of

Appeals for the Seventh District of Texas, in this behalf, and in all things to have it duly

recognized, obeyed and executed.

WITNESS, the Honorable Justices of our said Court, with the seal thereof

annexed, at the City of Amarillo on March 6, 2015.

Vivian Long

VIVIAN LONG, CLERK

FILE COPY
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JAN-31-2001
<PERIOD-START>                             MAY-01-2000
<PERIOD-END>                               JUL-31-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          11,632
<SECURITIES>                                         0
<RECEIVABLES>                                   81,273
<ALLOWANCES>                                   (4,548)
<INVENTORY>                                     61,763
<CURRENT-ASSETS>                               181,558
<PP&E>                                          93,228
<DEPRECIATION>                                (41,898)
<TOTAL-ASSETS>                                 284,505
<CURRENT-LIABILITIES>                          122,724
<BONDS>                                        118,723
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           195
<OTHER-SE>                                      41,169
<TOTAL-LIABILITY-AND-EQUITY>                   284,505
<SALES>                                        134,666
<TOTAL-REVENUES>                               134,666
<CGS>                                           91,122
<TOTAL-COSTS>                                   91,122
<OTHER-EXPENSES>                                22,664
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,394
<INCOME-PRETAX>                                 18,506
<INCOME-TAX>                                     6,969
<INCOME-CONTINUING>                             11,512
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,512
<EPS-BASIC>                                       0.59
<EPS-DILUTED>                                     0.59


</TABLE>
Exhibit 10.1


 


 





SECOND AMENDMENT TO EMPLOYMENT AGREEMENT


 


This Second Amendment
to the Employment Agreement dated as of July 5, 2016 (the “Employment Agreement”), dated as of May 5, 2017 (this
“Amendment”), is by and among Lilis Energy, Inc., a Nevada corporation (the “Company”), and
Abraham Mirman (“Executive”).


 


WHEREAS, the parties
hereto desire to amend the Employment Agreement as hereinafter set forth.


 


NOW, THEREFORE, in
consideration of the foregoing and the representations, warranties, covenants and agreements set forth herein, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally
bound hereby, agree as follows:


 


 1.        Cash Incentive Bonus. Section 5.3 of the Employment Agreement is hereby deleted and replaced in its entirety to read as follows: 




 


“5.3
       Reserved.”


 


2.       Additional
Representations and Warranties. This Amendment and the Employment Agreement, as amended hereby, constitute the legal, valid
and binding obligations of the parties hereto and are enforceable against each of the parties hereto in accordance with their respective
terms, subject only to the effect, if any, of (i) applicable bankruptcy and other similar laws affecting the rights of creditors
generally and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.


 


3.       Governing
Law. This Amendment shall be governed, construed and enforced in accordance with the Laws of the State of New York without
giving effect to the principles of conflicts of law thereof.


 


4.       Effect
on the Employment Agreement. The Employment Agreement is not modified or amended other than as expressly indicated herein,
and all other terms and conditions of the Employment Agreement shall remain in full force and effect. The Employment Agreement,
as amended hereby, shall remain in full force and effect and is hereby ratified and confirmed. Except as expressly set forth herein,
the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the
parties, nor constitute a waiver of any provision of the Employment Agreement (or an agreement to agree to any future amendment,
waiver or consent).


 


5.       Counterparts.
This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall
be considered one and the same agreement.


 


 


[Signature on the
following page]


 




     



     


    

 


 


IN WITNESS WHEREOF,
Lilis and Executive have caused this Amendment to executed as of the date first written above.


 


	 	LILIS ENERGY, INC.	 
	 	 	 	 	 
	 	 	 	 	 
	 	By:	/s/ General Merrill McPeak
	 
	 	 	Name: 	General Merrill McPeak
	 
	 	 	Title: 	Chairman of the Compensation 

Committee	 
	 	 	 	 	 
	 	 	 	 	 
	 	EXECUTIVE 	 
	 	 	 
	 	 	 
	 	By:	/s/ Abraham Mirman 	 
	 	 	Name: 	Abraham Mirman 	 
	 	 	Title: 	Chief Executive Officer
Editorial Note on Part 177
Editorial Note: Nomenclature changes to part 177 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 177.2510 Polyvinylidene fluoride resins. Polyvinylidene fluoride resins may be safely used as articles or components of articles intended for repeated use in contact with food, in accordance with the following prescribed conditions: ( a ) For the purpose of this section, the polyvinylidene fluoride resins consist of basic resins produced by the polymerization of vinylidene fluoride.
( b ) The finished food-contact article, when extracted at reflux temperatures for 2 hours with the solvents distilled water, 50 percent (by volume) ethyl alcohol in distilled water, and *n-*heptane, yields total extractives in each extracting solvent not to exceed 0.01 milligram per square inch of food-contact surface tested; and if the finished food-contact article is itself the subject of a regulation in parts 174, 175, 176, 177, 178 and § 179.45 of this chapter, it shall also comply with any specifications and limitations prescribed for it by that regulation. (Note: In testing the finished food-contact article, use a separate test sample for each required extracting solvent.)
( c ) In accordance with good manufacturing practice, finished food-contact articles containing the polyvinylidene fluoride resins shall be thoroughly cleansed prior to their first use in contact with food.
§ 338.1 Scope. ( a ) An over-the-counter nighttime sleep-aid drug product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this part and each general condition established in § 330.1 of this chapter.
( b ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.
### SERVE D MA Y 24 , 201 0 U.S
. DEPARTMEN T O FTRANSPORTATIO N

OFFIC E O FHEARING S WASHINGTON , D C
IN TH E MATTE RO F 

### NEWL Y WED S FOODS , INC
. FA A DOCKE T NO
. CP10SW000 3 (Civi l Penalt y Action ) DM S NO
. FA

A 2010-019 8
ORDE RO FDISMISSA L Th e Federa l Aviatio n Administratio n (hereinafte r referre dt o a s "Complainant" ) filed a Complain t

date dMarc h9 , 2010
. Newl y Wed s Foods , Inc. , (hereinafte r referre dt o a s "Respondent" ) filedaReques t

for Hearin g date dFebruar y 23 , 2010
. Responden t thereafte r

filedan Answe r

date d Apri l 6,2010
. O n May 11 , 2010 , Responden t aske dt o withdra w it s Reques t for hearing , citin g settlement
. 1 4 C.F.R
. § 13.21 5 states : "A t an y tim e befor e o r

durin g ahearing , a n agenc y attorne y may withdra w acomplain t

o r party ma y withdra w areques t for ahearin g withou t

th e consen t

o f th e administrativ e la w judge
. I f an agenc y attorne y withdraw s th e complain t o r apart y withdraw s th e reques t

for ahearin g an dth e answer , th e administrativ e la w judg e shal l dismis s th e proceeding s unde r

thi s subpart

withprejudice. " WHEREFORE , th e Respondent' s reques t t o withdra w it s Reques t

for Hearin g havin g bee n rea dan dconsidered , i t

i s ORDERE D a s follows : 1
. Respondent' s reques t t o withdra w it s Reques t

for Hearin g b e an di s hereb y granted ; an d Recedin

g b e an di s hereb y dismisse dwithprejudice
. Rj^hara C Goodwil l U.S
. Administrativ e La w Judg e
Attachment s - Servic e Lis tFA A Docke t No
. CP10SW0003 (Civi l Penalt y Action ) SERVIC E LIS T ORIGINA L& ON E COP Y Federa l Aviatio n Administratio n 80 0 Independenc e Avenue , S.W
. Washington , D C 2059 1 Attention : Hearin g Docke t Clerk , AGC-43 0 Wilbu r Wrigh t Buildin g - Suit e 2W1000 '

ON E COP Y Joh n J
. Seely , Responden t Senio r Vic e Presiden t Newly Wed s Food s 414 0 W
. Fullerto n Avenu e Chicago , I L6063 9 TEL : 773-292-3815 FAX : 773-292-242 3 Jame s Archier , Complainant' s Counse l Offic e o f th e Regiona l Counsel , ASW- 7 Southwes t

Regio n Federa l Aviatio n Administratio n 260 1 Meacha mBlvd. , Suit e 6 E For t Worth , T X 76193-000 7 TEL : 817-222-509 9 FAX : 817-222-5945/509 2 Th e Honorabl e Richar dC
. Goodwin , Administrativ e La w Judg e Offic e o f Hearings , M-2 0 U.S
. Departmen t

o f Transportatio n 120 0 Ne w Jerse y Avenue , S.E
. Eas t Buildin g Groun dFloor , Roo mEl2-32 0 Washington , D C 2059 0 TEL : Attorney-Adviso r 202-366-213 9 Lega l Assistan t

202-366-512 1 FAX : 202-366-753 6

' Service was b

y U.S
. Mail
. Fo

r servic e i n person o r b y expeditedcourier , us e the following address : Hearin g Docket , Federa

l Aviation Administration , 600 Independenc e Avenue , S.W. , Wilbu r Wrigh t Building - Roo

m 2014 , Washington , D

C 20591 , Attention : Hearing Docke t Clerk, AGC-430
.
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                         314,780
<SECURITIES>                                         0
<RECEIVABLES>                                  681,723
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      28,029,945
<DEPRECIATION>                              13,941,875
<TOTAL-ASSETS>                              31,248,206
<CURRENT-LIABILITIES>                       30,373,711
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     874,495
<TOTAL-LIABILITY-AND-EQUITY>                31,248,206
<SALES>                                      7,497,999
<TOTAL-REVENUES>                             7,497,999
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             6,799,949
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,216,787
<INCOME-PRETAX>                              1,156,097
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,156,097
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
Exhibit 35.1








ANNUAL
STATEMENT OF COMPLIANCE

Reference
is hereby made to that certain Pooling and Servicing Agreement dated as of March 1, 2013, by and among DEUTSCHE MORTGAGE &
ASSET RECEIVING CORPORATION, as Depositor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Master Servicer, WELLS FARGO BANK, NATIONAL
ASSOCIATION, as Special Servicer, U.S. BANK NATIONAL ASSOCIATION, as Trustee, and DEUTSCHE BANK TRUST COMPANY AMERICAS, as Certificate
Administrator, Paying Agent and Custodian, and PARK BRIDGE LENDER SERVICES LLC as Operating Advisor with respect to Commercial
Mortgage Pass-Through Certificates, Series COMM 2013-CCRE6 (the "Agreement"). Capitalized terms used herein not otherwise
defined shall have the meanings assigned in the Agreement.

Pursuant
to Section 10.11 of this Agreement, I, Daniel Bober, Executive Vice President of Commercial Mortgage Services do hereby certify
that:

| | 1. | A review of the activities of the Master Servicer during the period from
January 1, 2015 through December 31, 2015 (the “Reporting Period”), and of its performance per the Agreement during
such period has been made under my supervision, and
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 2. | To the best of my knowledge, based on such review, the Master Servicer has
fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IN
WITNESS WHEREOF, the undersigned has executed this Certificate as of the 4th day of March 2016.



Daniel
Bober

Executive Vice President

Wells Fargo Bank
#### § 510.202 Definitions.

The following definitions of terms apply when used in this subpart:

*CNADA* means an application for conditional approval of a new animal drug submitted under section 571 of the Federal Food, Drug, and Cosmetic Act, and includes all amendments and permissible supplements.

*Import tolerance* means a tolerance for a residue of a new animal drug not approved or conditionally approved for use in the United States, but present in any imported edible portion of any animal.

*NADA* means a new animal drug application submitted under section 512 of the Federal Food, Drug, and Cosmetic Act, including all amendments and permissible supplements, for approval of a new animal drug.

*Request* means a request to establish or amend an import tolerance.
Denied Order Entered September 22 , 2021

In The



### Court of Appeals

Fifth District of Texas at Dallas

No. 05

- 21

- 00219

- CV

IN RE TEKIN & ASSOCIATES, LLC

, Relator

Original Proceeding from the C o u nty Court at Law No. 2

Dallas County, Texas

Trial Court Cause No. CC

- 20

- 01986

- B

ORDER

Before Justices Osborne, Pedersen, III, and Goldstein

Based on the Court’s opinion of this date, we DENY relator’s petition for

writ of mandamus.

/Bill Pedersen, III/ /

BILL PEDERSEN, III

JUSTICE
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7299 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7299

 To authorize to be appropriated to the Secretary of Housing and Urban 
 Affairs, $1,500,000,000 to carry out the HOME Investment Partnership 
                    Program, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 7, 2024

   Mr. Schiff (for himself, Ms. Norton, Mrs. Watson Coleman, and Mr. 
    Gomez) introduced the following bill; which was referred to the 
                    Committee on Financial Services

_______________________________________________________________________

                                 A BILL

 
 To authorize to be appropriated to the Secretary of Housing and Urban 
 Affairs, $1,500,000,000 to carry out the HOME Investment Partnership 
                    Program, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. AUTHORIZATION OF APPROPRIATIONS.

    Subtitle A of title II of Cranston-Gonzales National Affordable 
Housing Act (42 U.S.C. 12741 et seq.) is amended by adding at the end 
the following:

``SEC. 227. AUTHORIZATION OF APPROPRIATIONS.

    ``(a) In General.--There is authorized to be appropriated, to the 
Secretary of Housing and Urban Affairs, $1,500,000,000, in each of 
fiscal years 2024, 2025, 2026, 2027, and 2028, to carry out this 
subtitle.
    ``(b) Additional Amount.--In addition the amount authorized to be 
appropriated pursuant to subsection (a), there is authorized to be 
appropriated $500,000,000, in each of fiscal years 2024, 2025, 2026, 
2027, and 2028, for projects conducted under this subtitle that build 
or rehabilitate childcare facilities.''.
                                 <all>
```
§ 524.1044f Gentamicin and betamethasone spray. ( a ) *Specifications.* Each milliliter of spray contains gentamicin sulfate equivalent to 0.57 milligram (mg) gentamicin base and betamethasone valerate equivalent to 0.284 mg betamethasone.
( b ) *Sponsors.* See Nos. 000061, 017033, 054925, 058005, and 058829 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer two spray actuations two to four times daily for 7 days.
( 2 ) *Indications for use.* For the treatment of infected superficial lesions caused by bacteria susceptible to gentamicin.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[71 FR 13542, Mar. 16, 2006, as amended at 72 FR 5929, Feb. 8, 2007; 74 FR 22822, May 15, 2009; 77 FR 3598, Jan. 25, 2012; 88 FR 16549, Mar. 20, 2023]